Exobiosphere and Voyager Expand ISS Missions as Demand for Microgravity Drug Discovery Rises
Voyager Technologies (NYSE: VOYG) and Exobiosphere have announced two additional research campaigns aboard the International Space Station (ISS), further expanding their collaboration to provide commercial biotechnology and drug discovery organizations with repeatable access to microgravity research. The new campaigns build on an agreement designed to transform orbital life-science research from an occasional, highly constrained opportunity into a more predictable and schedulable service for pharmaceutical, biotechnology and research organizations.
At the center of the expanded program is Exobiosphere’s Orbital High-Throughput Screening in Microgravity (OHTS) platform, a mid-deck-locker-class system developed to conduct automated drug screening and other biological experiments in the microgravity environment of low-Earth orbit. The OHTS platform is scheduled to be installed aboard the ISS in April 2027. Following installation, the newly announced campaigns are expected to launch in relatively close succession, with the first scheduled for a Commercial Resupply Services mission in June 2027 and the second targeted for the August–September 2027 timeframe.
The two campaigns will involve customers from different institutions and will address separate scientific objectives. Despite the differences in research programs, both investigations will use the same orbital platform and ISS infrastructure. Voyager Europe will provide mission management services under the companies’ existing master services agreement.
The expansion highlights the growing interest in using microgravity as a research environment for drug discovery and biotechnology. Microgravity can alter cellular behavior, molecular interactions, protein organization and other biological processes, potentially creating experimental conditions that are difficult to reproduce on Earth. For researchers studying drug candidates, disease mechanisms and biological responses, these differences can provide another experimental dimension alongside conventional laboratory and animal models.
“Every one of these missions matters to the researchers behind it, and together they tell us something important about where this industry is heading,” said Matt Magaña, president of Space, Defense and National Security at Voyager. He said that multiple organizations with unrelated scientific objectives booking time on the same orbital platform within a single year demonstrates increasing commercial activity in the sector.
Magaña added that commercial research in low-Earth orbit is increasingly becoming something customers can incorporate into their research planning, rather than treating space-based experiments as isolated projects. Voyager aims to support that transition by providing infrastructure and mission-management capabilities that can make access to orbital research more routine.
OHTS Designed to Support Multiple Research Campaigns
A key feature of Exobiosphere’s OHTS platform is its ability to be resupplied and reconfigured for successive research programs. Rather than functioning as a single-use experiment, the system is intended to accommodate multiple campaigns over time.
Samples, test compounds and consumables can be exchanged between campaigns, while the scientific configuration of the platform can be adapted according to the objectives of each investigation. This approach allows a single orbital system to support independent research programs conducted by different organizations.
The model also creates the potential for successive campaigns to generate complementary datasets. Results from one experiment can help inform subsequent investigations, while standardized experimental procedures can make results easier to compare across different studies.
According to Exobiosphere, each campaign can conduct thousands of experiments using standardized well plates. Importantly, corresponding control experiments are performed on Earth under matched conditions. The paired orbital and ground experiments are intended to provide researchers with the reference data needed to interpret biological effects observed in microgravity.
This experimental design could be particularly important for pharmaceutical and biotechnology companies seeking actionable information rather than simply conducting exploratory research in space. By comparing microgravity results with Earth-based controls, researchers can examine which biological changes are specifically associated with the orbital environment and which are also observed under conventional laboratory conditions.
Kyle Acierno, chief executive officer of Exobiosphere, said researchers from pharmaceutical and biotechnology organizations frequently ask what practical information they can expect to receive from an orbital research program.
“With OHTS, the answer is structured data — thousands of experiments per campaign, standardized, paired with matched ground controls, and generated in a way that it can be used to train models, support new IP and feed real discovery programs,” Acierno said.
He said this data-oriented approach is intended to make orbital research something organizations can incorporate into longer-term development programs rather than treating it solely as a specialized research expense.
Potential Role in Drug Discovery
The use of microgravity for pharmaceutical research has attracted increasing attention as commercial space infrastructure develops. Researchers have investigated how reduced gravity can affect protein crystallization, cellular organization, tissue models and other biological systems. The ISS provides an established orbital laboratory where experiments can be performed under controlled conditions and subsequently compared with Earth-based controls.
High-throughput screening could broaden the types of drug discovery investigations conducted in orbit. Instead of examining only a small number of samples, an automated platform can process larger numbers of experimental conditions, compounds or biological measurements.
For biotechnology companies, such capabilities may allow microgravity to become one component of a broader research workflow. Data generated in orbit can potentially be combined with conventional laboratory datasets, computational models and artificial intelligence tools. Exobiosphere has positioned its OHTS platform around this type of data generation, with the goal of producing standardized experimental outputs that can contribute to discovery programs.
The ability to schedule multiple campaigns on the same platform is another important aspect of the model. Traditionally, space-based biological research has involved significant logistical planning because researchers must coordinate payload development, safety reviews, launch opportunities, station integration and orbital operations. A recurring platform approach is intended to streamline those processes for subsequent customers.
Voyager Europe to Manage Mission Integration
Under the expanded agreements, Voyager Europe will provide program management, ISS mission integration and mission provisioning services for each campaign. These responsibilities include safety and verification activities conducted according to NASA Safety Review standards, manifesting payloads on ISS Program Commercial Resupply Services vehicles, coordinating on-orbit operations and managing the return of samples to Earth.
Voyager will perform this work with its affiliate Nanoracks LLC, doing business as Voyager Space Solutions. The affiliate is responsible for final payload processing, NASA-required pre-flight preparations and console operations from its Houston-area facility.
The combination of mission-management expertise, payload processing and ISS integration is intended to give research customers a single operational framework through which their experiments can progress from development and preparation to launch, execution and sample return.
“This cadence is only possible because of NASA, the ISS Program and the safety and integration teams we work alongside who turn scientific ambitions into launch dates,” said Mattia Pianorsi, managing director of Voyager Europe.
Pianorsi said Voyager’s objective is to make the process sufficiently predictable for research organizations to incorporate orbital campaigns into their broader scientific programs. He also highlighted the work being conducted by Voyager teams in Torino, Italy, and Houston in supporting repeated missions.
Building a Recurring Commercial Research Model
The two newly announced campaigns represent another step toward establishing a recurring commercial model for microgravity biotechnology research. Rather than relying on individual, standalone missions, Exobiosphere and Voyager are developing an operating framework in which a common orbital platform can support a series of customers and scientific objectives.
For pharmaceutical and biotechnology companies, the ability to schedule experiments around defined launch windows could make it easier to incorporate space-based research into development timelines. Reusable experimental infrastructure may also reduce the need to design an entirely new system for every investigation, allowing researchers to focus more heavily on the scientific questions and compounds being evaluated.
The planned April 2027 installation of OHTS, followed by campaigns in June and August–September 2027, provides a concrete example of this recurring approach. Each campaign will have its own scientific objectives while benefiting from common infrastructure and mission-management processes.
The collaboration also illustrates the broader evolution of the commercial space economy beyond satellite communications and transportation. Life sciences and pharmaceutical research are emerging as areas where commercial orbital infrastructure can support specialized applications. As more companies seek access to microgravity, platforms capable of conducting standardized, repeatable biological experiments could become an important component of the emerging space-based research ecosystem.
For Exobiosphere, the partnership provides a pathway to deploy its high-throughput screening capabilities in orbit and generate datasets designed for downstream scientific applications. For Voyager, the campaigns expand its role in supporting commercial research missions and demonstrate how established ISS infrastructure can be used repeatedly by different customers.
The companies said the new campaigns reinforce Voyager’s track record of facilitating commercial access to low-Earth orbit while advancing Exobiosphere’s broader objective of using microgravity research to support discoveries intended to extend and improve life on Earth and in space.
With the OHTS platform scheduled for ISS installation in 2027 and multiple campaigns already planned afterward, the collaboration represents an effort to make microgravity-based drug discovery more systematic, repeatable and accessible to commercial researchers. As pharmaceutical and biotechnology organizations continue exploring new experimental models and data-generation technologies, recurring orbital screening could provide another research environment for investigating biological processes and potential therapeutic opportunities.
About Voyager Technologies
Voyager Technologies is a defense and space technology company committed to advancing and delivering transformative, mission-critical solutions. By tackling the most complex challenges, Voyager aims to unlock new frontiers for human progress, fortify national security, and protect critical assets from ground to space. For more information visit: voyagertechnologies.com and follow on LinkedIn and X.
About Exobiosphere
Exobiosphere is a space biotechnology company developing autonomous high-throughput platforms for drug discovery and manufacturing in microgravity. By running thousands of standardized experiments against matched ground controls, the company produces orbital datasets and that pharmaceutical, biotechnology and research partners can build discovery programs on — making space a routine, essential part of the R&D pipeline